Tags

Type your tag names separated by a space and hit enter

Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
Clin Infect Dis. 2020 09 12; 71(6):1410-1412.CI

Links

PMC Free PDF

Authors+Show Affiliations

O'Brien TR
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Thomas DL
Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
Jackson SS
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Prokunina-Olsson L
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Donnelly RP
Division of Biotechnology Research and Review II, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Hartmann R
Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark.

MeSH

BetacoronavirusCOVID-19Coronavirus InfectionsHumansImmunity, InnateInterferon-gammaInterferonsLungPandemicsPneumonia, ViralSARS-CoV-2Virus ReplicationCOVID-19 Drug Treatment

Pub Type(s)

Journal Article
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

32301957

Citation

O'Brien, Thomas R., et al. "Weak Induction of Interferon Expression By Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 71, no. 6, 2020, pp. 1410-1412.
O'Brien TR, Thomas DL, Jackson SS, et al. Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019. Clin Infect Dis. 2020;71(6):1410-1412.
O'Brien, T. R., Thomas, D. L., Jackson, S. S., Prokunina-Olsson, L., Donnelly, R. P., & Hartmann, R. (2020). Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 71(6), 1410-1412. https://doi.org/10.1093/cid/ciaa453
O'Brien TR, et al. Weak Induction of Interferon Expression By Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019. Clin Infect Dis. 2020 09 12;71(6):1410-1412. PubMed PMID: 32301957.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019. AU - O'Brien,Thomas R, AU - Thomas,David L, AU - Jackson,Sarah S, AU - Prokunina-Olsson,Ludmila, AU - Donnelly,Raymond P, AU - Hartmann,Rune, PY - 2020/04/09/received PY - 2020/04/16/accepted PY - 2020/4/18/pubmed PY - 2020/9/25/medline PY - 2020/4/18/entrez KW - MERS-CoV KW - SARS-CoV KW - innate immunity KW - severe acute respiratory syndrome KW - virology SP - 1410 EP - 1412 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 71 IS - 6 SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/32301957/Weak_Induction_of_Interferon_Expression_by_Severe_Acute_Respiratory_Syndrome_Coronavirus_2_Supports_Clinical_Trials_of_Interferon_λ_to_Treat_Early_Coronavirus_Disease_2019_ DB - PRIME DP - Unbound Medicine ER -